(Press-News.org) A large prospective, randomized clinical trial in patients with advanced breast cancer has found that the use of liquid biopsy blood tests for early detection of a treatment-resistance mutation, followed by a switch to a new type of treatment, substantially extends the period of tumor control compared to standard care.
The SERENA-6 study, published June 1 in the New England Journal of Medicine and presented concurrently at the annual meeting of the American Society for Clinical Oncology, was conducted at multiple medical centers, principally in Europe, East Asia and the United States, including at Weill Cornell Medicine and three affiliated NewYork-Presbyterian campuses: NewYork-Presbyterian/Weill Cornell Medical Center, NewYork-Presbyterian Brooklyn Methodist Hospital, and NewYork-Presbyterian Queens. It is one of the first demonstrations that treatment switching guided by liquid biopsy results brings better outcomes for patients.
“The main message here is that liquid biopsy technology allows us to intervene sooner when the tumor burden is lower and the chance of a good outcome is higher,” said study co-author Dr. Massimo Cristofanilli, professor of medicine at Weill Cornell Medicine and an oncologist at NewYork-Presbyterian/Weill Cornell Medical Center.
Dr. Cristofanilli, an expert on the use of liquid biopsy technology for cancer monitoring and early cancer detection, helped design and oversee the SERENA-6 study as a member of its steering committee.
The study, which was sponsored by Astra Zeneca, enrolled patients with advanced forms of estrogen receptor (ER) positive, HER2 receptor-negative breast cancer, which is driven by the overactivity of growth-promoting estrogen receptors on tumor cells. Standard treatment includes drugs called aromatase inhibitors that block the production of ER-stimulating estrogen hormones. However, tumors treated this way often start growing and spreading again because they develop mutations in the ESR1 gene that keep estrogen receptors active even when estrogen hormone levels are low or absent.
The trial was set up to determine if patients would benefit from early detection of ESR1 mutations with liquid biopsy-type blood tests, followed by an immediate switch to an experimental new breast cancer drug called camizestrant, which reduces the number of estrogen receptors.
The researchers screened more than 3,300 patients at 264 different clinical sites in 23 countries. The 315 who had detectable ESR1 mutations but no symptomatic or medical imaging evidence of tumor progression were randomly assigned to stop taking an aromatase inhibitor and start taking camizestrant, or to stick to standard treatment including an aromatase inhibitor.
The results showed that patients who switched to camizestrant tended to have a longer period of tumor non-progression (median 16.0 months vs. 9.2 months), and a much longer time to deterioration in their overall health status and quality of life (median 23.0 months vs. 6.4 months).
The researchers considered these differences to be both statistically significant and clinically meaningful. Camizestrant also was well tolerated, with low rates of treatment discontinuation.
Dr. Cristofanilli, who is also the scientific director of the Englander Institute for Precision Medicine and the associate director of precision oncology at the Sandra and Edward Meyer Cancer Center, said that he expects the strategy demonstrated in this study to be applicable more generally when doctors monitor for ER-positive breast cancer recurrence after treatment. He noted as well that not only breast cancer but also many other cancer types have potential treatment-resistance mutations that can be detected early with liquid biopsy techniques.
END
Switch to experimental drug after liquid biopsy detection of breast cancer recurrence improves outcomes
2025-06-01
ELSE PRESS RELEASES FROM THIS DATE:
Alliance presents results from phase III ATOMIC trial combining atezolizumab with chemotherapy for patients with stage III dMMR colon cancer at ASCO 2025
2025-06-01
June 1, 2025 — The Alliance for Clinical Trials in Oncology announced today results from ATOMIC (A021502), a phase III trial evaluating standard chemotherapy alone or combined with atezolizumab (Tecentriq®) in treating patients who have surgically resected stage III colon cancer and deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR). The study, sponsored by the National Cancer Institute (NCI) and conducted in partnership with Genentech, a member of the Roche Group, met its primary endpoint, demonstrating a statistically ...
Immunotherapy boosts chemotherapy in combating stage 3 colon cancer
2025-06-01
Late-breaking abstract featured at ASCO 2025
ROCHESTER, Minn. — Colon cancer is the third most prevalent form of cancer in the U.S., and while screening has helped detect and prevent colon cancer from spreading, major advancements in treating colon cancer have lagged.
Now, new research led by Mayo Clinic Comprehensive Cancer Center found that adding immunotherapy to chemotherapy after surgery for patients with stage 3 (node-positive) colon cancer — and with a specific ...
AI deciphers plant DNA: language models set to transform genomics and agriculture
2025-06-01
By leveraging the structural parallels between genomic sequences and natural language, these AI-driven models can decode complex genetic information, offering unprecedented insights into plant biology. This advancement holds promise for accelerating crop improvement, enhancing biodiversity conservation, and bolstering food security in the face of global challenges.
Traditionally, plant genomics has grappled with the intricacies of vast and complex datasets, often limited by the specificity of traditional machine learning models and the scarcity of annotated ...
Endophytic fungi from halophyte Sesuvium portulacastrum enhance maize growth and salt tolerance
2025-06-01
This research provides key insights into how microbial inoculants can offer a cost-effective, eco-friendly strategy to enhance crop resilience in saline soils.
Soil salinization is a major global challenge that severely impacts agricultural productivity, with over 3% of the Earth’s terrestrial surface affected. It threatens food security by causing osmotic, ionic, and oxidative stress, which can reduce crop yields by more than 50%. Traditional remediation methods, such as physical and chemical interventions, are often prohibitively expensive. However, ...
Quality of kids’ diets linked with dad’s eating habits as a teen
2025-05-31
While moms have traditionally gotten much of the focus when it comes to children’s eating habits, a new study highlights the importance of dads in shaping a child’s relationship with food. According to the study, young children were more likely to consume the recommended amount of fruits and vegetables if their father ate a healthier diet during his teen years.
The study is based on data from 669 men who answered questionnaires about their eating habits during adolescence and then, years later, provided information about their attitudes and behaviors surrounding their children’s diet.
“Our ...
Alliance trial shows dual immunotherapy improves progression-free survival in advanced squamous cell skin cancer
2025-05-31
May 31, 2025 — A phase II clinical trial led by the Alliance for Clinical Trials in Oncology has met its primary endpoint, demonstrating that the combination of avelumab and cetuximab improved progression-free survival (PFS) compared to avelumab alone in patients with advanced cutaneous squamous cell carcinoma (cSCC). The results, presented as an oral abstract at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, and published in the Journal of Clinical Oncology, suggest a promising new approach for patients with this aggressive form of skin cancer.
“These results show that combining immune checkpoint inhibition targeting the PD-1: PD-L1 pathway ...
Insights from immunotherapy trial inform new approaches to treating advanced skin cancer
2025-05-31
In patients with an advanced type of skin cancer called cutaneous squamous cell carcinoma (cSCC), those who received the combination of the immunotherapy drug avelumab and targeted agent cetuximab had almost four times longer median progression-free survival compared to patients who received avelumab alone, according to the results of a phase 2 trial presented today at the American Society of Clinical Oncology (ASCO) meeting and concurrently published in the Journal of Clinical Oncology.
“It is both an honor and humbling to develop clinical trials ...
Genome breakthrough reveals secrets behind rapid growth and invasiveness of tropical vine Merremia boisiana
2025-05-31
Merremia boisiana, a member of the Convolvulaceae family, a fast-growing vine native to tropical rainforests and known for its vibrant golden flowers and astonishing climbing ability, grows at speeds exceeding 12 cm per day, often overwhelming native vegetation and disrupting forest ecosystems. Despite its ecological importance and genetic proximity to economically vital crops like sweet potato (Ipomoea batatas), little was known about its genomic makeup until now.
A study (DOI:10.48130/tp-0025-0007) published in Tropical Plants on 24 March 2025 by Fei Chen and Wenquan Wang’s team, Hainan University, marks a significant leap ...
Transforming the certification process of 3D-printed critical components
2025-05-30
At present, it takes an average of 18 months for a supercomputer to evaluate a single 3D part and accurately predict its lifespan or expected date of failure. The Defense Advanced Research Projects Agency (DARPA)’s Structures Uniquely Resolved to Guarantee Endurance (SURGE) program has tasked grantees with compressing this evaluation time to three days and significantly simplifying the process so that it can be performed on a laptop computer.
Four members of the Texas A&M University faculty have responded to that ...
UC Davis clinical trial shows biomarkers hold clue in treating aggressive prostate cancer
2025-05-30
Many men with aggressive prostate cancer can experience a high rate of recurrence despite treatment.
A new Phase 2 clinical trial at UC Davis Comprehensive Cancer Center unveiled clues as to why these patients are doing poorly and may offer hope in the form of targeted therapy.
The findings will be presented at the annual American Society of Clinical Oncology (ASCO) conference on June 3 in Chicago. .
Pilot trial sheds new clues ...